# Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

> **NCT01315236** · PHASE2 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 90 (actual)

## Conditions studied

- Mycobacterium Infections, Nontuberculous

## Interventions

- **DRUG:** Liposomal amikacin for inhalation (LAI)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01315236
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-19
- **Primary completion:** 2014-08-18
- **Final completion:** 2015-06-18
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2019-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01315236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01315236, "Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01315236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*